These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 17845141)

  • 1. Trial design for cancer (cell)-specific anticancer therapies.
    van Alphen RJ; Verweij J; Eskens FA
    Expert Opin Ther Targets; 2007 Sep; 11(9):1137-41. PubMed ID: 17845141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [New anticancer drugs: much ado about nothing?].
    Zimmermann S; Betticher D
    Rev Med Suisse; 2014 Apr; 10(425):788, 790-3. PubMed ID: 24791424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Envisioning the future of early anticancer drug development.
    Yap TA; Sandhu SK; Workman P; de Bono JS
    Nat Rev Cancer; 2010 Jul; 10(7):514-23. PubMed ID: 20535131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetics and oncology.
    Mummaneni P; Shord SS
    Pharmacotherapy; 2014 May; 34(5):495-505. PubMed ID: 24619798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
    Adis International Ltd
    Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strategy for the development of novel anticancer drugs.
    Saijo N; Tamura T; Nishio K
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S97-101. PubMed ID: 12856152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical trial design for target-based therapy.
    Fox E; Curt GA; Balis FM
    Oncologist; 2002; 7(5):401-9. PubMed ID: 12401902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The development of molecularly targeted anticancer therapies: an Eli Lilly and Company perspective.
    Perry WL; Weitzman A
    Clin Adv Hematol Oncol; 2005 Mar; 3(3):199-202, 237-8. PubMed ID: 16166991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endpoints and other considerations in phase I studies of targeted anticancer therapy: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT).
    Booth CM; Calvert AH; Giaccone G; Lobbezoo MW; Seymour LK; Eisenhauer EA
    Eur J Cancer; 2008 Jan; 44(1):19-24. PubMed ID: 17890079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel agents: clinical trial design.
    Tan AR; Swain SM
    Semin Oncol; 2001 Oct; 28(5 Suppl 16):148-53. PubMed ID: 11706406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular biological design of novel antineoplastic therapies.
    Vulfovich M; Saba N
    Expert Opin Investig Drugs; 2004 Jun; 13(6):577-607. PubMed ID: 15174947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early oncology clinical trial design in the era of molecular-targeted agents.
    Brunetto AT; Kristeleit RS; de Bono JS
    Future Oncol; 2010 Aug; 6(8):1339-52. PubMed ID: 20799878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Personalised medicine for cancer: from drug development into clinical practice.
    Jain KK
    Expert Opin Pharmacother; 2005 Aug; 6(9):1463-76. PubMed ID: 16086635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving the evaluation of new cancer treatments: challenges and opportunities.
    Rothenberg ML; Carbone DP; Johnson DH
    Nat Rev Cancer; 2003 Apr; 3(4):303-9. PubMed ID: 12671669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Future directions of anticancer drug development in Japan].
    Akaza H; Kawai K; Tsuruo T; Tsukagoshi S; Aiba K; Shimada Y; Kakeji Y; Ishikawa H; Ikeda T; Nakamura S; Tamura T; Yamamoto N; Isonishi S; Hinotsu S; Hirose M; Katsura J
    Gan To Kagaku Ryoho; 2008 Feb; 35(2):351-60. PubMed ID: 18281781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progress in the clinical development of new marine-derived anticancer compounds.
    Jimeno J; López-Martín JA; Ruiz-Casado A; Izquierdo MA; Scheuer PJ; Rinehart K
    Anticancer Drugs; 2004 Apr; 15(4):321-9. PubMed ID: 15057135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Marine-derived anticancer agents in clinical trials.
    Schwartsmann G; Da Rocha AB; Mattei J; Lopes R
    Expert Opin Investig Drugs; 2003 Aug; 12(8):1367-83. PubMed ID: 12882622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Compressing drug development timelines in oncology using phase '0' trials.
    Kummar S; Kinders R; Rubinstein L; Parchment RE; Murgo AJ; Collins J; Pickeral O; Low J; Steinberg SM; Gutierrez M; Yang S; Helman L; Wiltrout R; Tomaszewski JE; Doroshow JH
    Nat Rev Cancer; 2007 Feb; 7(2):131-9. PubMed ID: 17251919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular-targeted therapies: lessons from years of clinical development.
    Rosa DD; Ismael G; Lago LD; Awada A
    Cancer Treat Rev; 2008 Feb; 34(1):61-80. PubMed ID: 17826917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review: new biological insights in early clinical studies.
    Maur M; Sessa C
    Hematol Oncol; 2007 Jun; 25(2):53-7. PubMed ID: 17351979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.